CD200 promotes immunosuppression in the pancreatic tumor microenvironment

Fouad Choueiry(The Ohio State University), Thomas A. Mace(The Ohio State University)

Journal for ImmunoTherapy of Cancer

June 1, 2020

10.1136/jitc-2019-000189

Cited by 99

Related Papers

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

|Gut|2016|540

Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function

|Scientific Reports|2019|69

Tomatidine targets ATF4-dependent signaling and induces ferroptosis to limit pancreatic cancer progression

|iScience|2023|34

Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma

|Cancers|2021|31

Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer

|Oncotarget|2015|16